Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
|Videos|August 24, 2011
Dr. Yoneda on Bronchoscopy Tools and Procedures
Author(s)Ken Y. Yoneda, MD
Dr. Ken Yoneda from UC Davis Cancer Center Discusses Bronchoscopy Tools and Procedures
Advertisement
Ken Y. Yoneda, MD, associate professor of internal medicine, pulmonary and critical care, UC Davis Cancer Center, discusses that bronchoscopy is still an evolving area. The various tools available include electromagnetic navigation, computed tomography navigation, and ultrasound. These methods provide not only access to the tumors for diagnosis but also for staging and biomarker testings.
Advertisement
Related to this article
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
Divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib in the phase III Krascendo 1 trial in previously treated KRAS G12C–mutant NSCLC.
Faculty members gathered at an OncLive Scientific Interchange and Workshop to discuss individualizing care in EGFR-mutated NSCLC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
SB27, a proposed pembrolizumab biosimilar, met primary end points in phase 1 pharmacokinetic and a phase 3 efficacy studies.
Advertisement
Advertisement
Trending on OncLive
1
Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma
2
Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond
3
STRIDE Plus TACE With/Without Lenvatinib Improves Responses in Embolization-Eligible HCC
4
Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC
5